تاثیر 16 هفته محدودیت کالریک بر سطوح آیریزین سرم و شاخص مقاومت به انسولین در زنان چاق کم تحرک

محورهای موضوعی : میکروبیولوژی مواد غذایی

اعظم رمضانخانی ¹ , رحمان سوری ²

1 - دکتری تخصصی فیزیولوژی ورزش، دانشگاه تهران، تهران، ایران
2 - دانشیار گروه فیزیولوژی ورزش، دانشگاه تهران، تهران، ایران

تاریخ دریافت : 1395/12/01 تاریخ پذیرش : 1395/12/01 تاریخ انتشار : 1396/01/01

کلید واژه: آیریزین, زنان چاق کم تحرک, شاخص مقاومت به انسولین, محدودیت کالری,

چکیده مقاله :

مقدمه: آیریزین مایوکاین جدیدی است که از پروتئین غشایی آزاد شده و تأثیرات مثبتی بر متابولیسم دارد. هدف از پژوهش 5 حاضر، بررسی تأثیر محدودیت کالری بر سطوح آیریزین سرم و شاخص مقاومت به انسولین در زنان چاق کم تحرک می باشد. سال؛ 41/40±4/٥3 انحراف استاندارد ± نفر از زنان مراجعه کننده به خانههای سلامت غرب تهران (میانگین 20 : مواد و روشها 14/٦±٦9/٧ نفر) قرار گرفتند. افراد گروه محدودیت 10 نفر) و کنترل ( 10( کیلوگرم)، به طور تصادفی در دو گروه محدودیت کالری ٦ % کمتر از انرژی محاسبه شده روزانه دریافت نمودند. میزان آیریزین سرم، گلوکز و انسولین و مقاومت به انسولین 2٥ کالری، در دوره مداخله، HOMA با روش هفته مداخله اندازهگیری گردید. 1٦ - (شاخص مقاومت به انسولین) قبل و بعد از IR (نسبت دور کمر به دور لگن)، آیریزین سرم، گلوکز ناشتا، انسولین ناشتا WHR ، (نمایه توده بدن) BMI یافتهها: کاهش معناداری در وزن، HOMA و HOMA - در گروه محدودیت کالری مشاهده گردید. بین تغییرات آیریزین سرم با تغییرات وزن، IR همبستگی WHR - و IR p معناداری مشاهده گردید ( <0.05.) HOMA و WHR ،BMI نتیجه گیری :همبستگی معناداری بین سطوح آیریزین سرم با هفته محدودیت کالری بر 1٦ - وجود دارد. IR کاهش میزان آیریزین سرم و شاخص مقاومت به انسولین در زنان چاق کم تحرک مؤثر است.

چکیده انگلیسی:

Introduction: Irisin is a new adipokine that is released from membrane protein FNDC5 and has positive effects on metabolism. The aim of this study was to survey the effects of caloric restriction on serum irisin levels and insulin resistance index in obese sedentary women. Materials and Methods: Twenty women (Mean± SD: 41.40±4.53 years; 76.69±6.14 Kg) who referred to home health of west of Tehran were divided into two groups; caloric restriction group (n=10) and control group (n=10). The calorie restriction group, in the intervention period, received 25% less than the estimated daily energy requirement. Serum irisin, glucose, insulin levels and insulin resistance using HOMA-IR were measured before and after 16 weeks. Results: Weight, BMI (body mass index), WHR (waist to hip ratio), serum irisin, fasting glucose, fasting insulin and HOMA-IR were decreased significantly in the caloric restriction group. Significant correlation were observed between changes of serum irisin levels with changes of body weight, WHR, HOMA-IR, fasting glucose and fasting insulin levels (p<0.05). Conclusion: There is a significant correlation between serum irisin levels with BMI, WHR and HOMA-IR. 16 weeks of caloric restriction is effective in reduction of serum irisin levels and insulin resistance in obese sedentary women.

منابع و مأخذ:

Boström, P., Wu, J., Jedrychowski, M.P., Korde, A., Ye, L. & Lo, J. C. (2012). A PGC1α dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature, 481(7382), 463-468.

Choi, Y. K., Kim, M. K., Bae, K. H., Seo, H., Jeong, J. Y. & Lee, W. K. (2013). Serum irisin levels in new-onset type 2 diabetes. Diabetes Res Clin Pract, 100(1), 96-101.

Crujeiras, A. B., Pardo, M., Arturo, R. R., Santiago, N. C., Zulet, M. & Martínez, J. A. (2014). Longitudinal variation of circulating irisin after an energy restriction‐induced weight loss and following weight regain in obese men and women. American Journal of Human Biology, 26(2), 198-207.

Crujeiras, A. B., Zulet, M. A.,  Lopez-Legarrea, P., Iglesia, R., Pardo, M. & Carreira, M. C. (2014). Association between circulating irisin levels and the promotion of insulin resistance during the weight maintenance period after a dietary weight-lowering program in obese patients. Metabolism, 63(4), 520-531.

Hammond, K. A. (2000). Dietary clinical assessment. In: L Kathleen Mahan LX, Sylvia “Escott-stump” (Editors). Krause’s Food & diet therapy. 10^th ed. Philadelphia: W.B Saunders Company, Philadelphia, 353-357.

Huh, J. Y., Panagiotou, G., Mougios, V., Brinkoetter, M., Vamvini, M. T., Schneider, B. E. (2012). FNDC5 and irisin in humans. I. Predictors of circulating concentrationsin serum and plasma and II. mRNA expression and circulating concentrationsin response to weight loss and exercise. Metabolism, 61,1725–1738.

Huth, C., Marette, A., Tremblay, A., Weisnagel, S. J., Mauriège, P. & Lacaille, M. (2014). Plasma irisin is associated with insulin resistance in men. FASEB Journal, 28(1), 854.

Iglesia, R., Lopez-Legarrea, P., Crujeiras, A. B., Pardo, M., Casanueva, F. & Zulet, M. A. (2014). Plasma irisin depletion under energy restriction is associated with improvements in lipid profile in metabolic syndrome patients. Clinical Endocrinology, 81(2), 306-311.

Lee, P., Linderman, J. D., Smith, S., Brychta, R. J., Wang, J. & Idelson, C. (2014). Irisin and FGF21 are cold-induced endocrine activators of brown fat function in humans. Cell Metab, 19, 302–309.

Liu, J., Wong, M., ChingToy, W., Tan, C., Liu, S. & Ng, X. (2013). Lower circulating irisin is associated with type 2 diabetes mellitus.Journal of Diabetes and its Complications, 27(4), 365-369.

Lopez-Legarrea, P., Iglesia, R., Crujeiras, A. B., Pardo, M., Casanueva, F. & Zulet, M. A. (2014). Higher baseline irisin concentrations are associated with greater reductions in glycemia and insulinemia after weight loss in obese subjects. Nutrition & Diabetes, 4, e110.

Moreno-Navarrete, J. M., Ortega, F., Serrano, M., Guerra, E., Pardo, G. & Tinahones, F. (2013). Irisin is expressed and produced by human muscle and adipose tissue

 

in association with obesity and insulin resistance. Ndocrinol Metab, 98(4), E769–E778.

Moreno, M., Moreno-Navarrete, J. M., Serrano, M., Ortega, F., Delgado, E. & Sanchez-Ragnarsson, C. (2015). Circulating Irisin Levels Are Positively Associated with Metabolic Risk Factors in Sedentary Subjects. PLoS ONE, 10(4), 1-11.

Norheim, F., Langleite, T. M., Hjorth, M., Holen, T., Kielland, A., Stadheim, H. K. (2013). The effects of acute and chronic exercise on PGC1-α, irisin and browning of subcutaneous adipose tissue in humans. FEBS J, 281(3), 739-749.

Park, K. H., Zaichenko, L., Peter, P., Davis, C. R., Crowell, J.  A. & Mantzoros, C. S. (2014). Diet quality is associated with circulating C-reactive protein but not irisin levels in humans. Metabolism, 63, 233–241.

Polyzos, S. A., Kountouras, J., Anastasilakis, A. D., Geladari, E.V. & Mantzoros, C. S. (2014). Irisin in patients with nonalcoholic fatty liver disease. Metabolism, 63(2), 207-217.

Raschke, S., Elsen, M., Gassenhuber, H., Sommerfeld, M., Schwahn, U., Brockmann, B. (2013). Evidence against a beneficial effect of irisin in humans. PLOS ONE, 8, e73680.

 Reinehr, T.,  Elfers, C.,  Lass, N. &  Roth, C. L. (2015). Irisin and Its Relation to Insulin Resistance and Puberty in Obese Children: A Longitudinal Analysis. JCEM, 100(5), 1208.

Roca-Rivada, A., Castelao, C., Senin, L.L., Landrove, M.O., Baltar, J., Belén Crujeiras, A. (2013). FNDC5/irisin is not only a myokine but also an adipokine. PLOS ONE, 8, e60563.

Sesti, G., Andreozzi, F., Fiorentino, T. V., Mannino, G.C., Sciacqua, A. & Marini, M. A. (2014). High circulating irisin levels are associated with insulin resistance and vascular atherosclerosis in a cohort of nondiabetic adult subjects. Acta Diabetologica, 51(5), 705-713.

Stengel, A., Hofmann, T., Goebel-Stengel, M., Elbelt, U., Kobelt, P. & Klapp, B. F. (2013). Circulating levels of irisin in patients with anorexia nervosa and different stages of obesity – Correlation with body mass index. Peptides, 39, 125-130.

Suleyman, A. (2014). Three new players in energy regulation: Preptin, adropin and irisin. Peptides, 56, 94–110.

Takeshi, Y. & Masayuki, S. (2015). Activation and recruitment of brown adipose tissue as anti-obesity regimens in humans. Annals of Medicine, 47(2), 133-141.

Zhang, H. J.,  Zhang, X. F., Ma, Z.M., Pan, L., Chen, Z. & Han, H. W. (2013).  Irisin is inversely associated with intrahepatic triglyceride contents in obese adults. Journal of Hepatology, 59(3), 557-562.